TLR7配体Loxoribine抗乙型肝炎病毒的体外实验研究

目的 探讨TLR7配体Loxoribine对乙型肝炎病毒的抑制作用。方法 采用MTT法观察Loxoribine药物对体外培养HepG2.2.15细胞的毒性作用，ELISA及荧光定量PCR法分析药物对细胞培养上清液中HBsAg、HBeAg及HBV DNA含量的影响。结果 低浓度Loxoribine对体外培养的HepG2.2.15细胞生长有一定抑制作用，但随着药物浓度增高，对细胞生长并无明显毒性作用。Loxoribine可有效地抑制HepG2.2.15细胞HBV DNA的复制及HBsAg的分泌，并随着药物浓度的增加和作用时间的延长，对HBsAg抑制率增大，而对HBeAg的分泌无抑制作用。结论 Loxoribine在体外具有抗乙型肝炎病毒的作用。

Anti-HBV activity of TLR7 ligand Loxoribine in vitro

Objective To study the anti-HBV effect of TLR7 ligand Loxoribine in vitro.Methods HepG2.2.15 cells were cultured in vitro for treatment with TLR ligand Loxoribine.MTT,enzyme-linked immunosorbent assay(ELISA) and real-time PCR were used to quantify the cytotoxicity in HepG2.2.15 cells,extracellular HBsAg and HBeAg,and extracellular HBV DNA,respectively.Results Low concentration of Loxoribine inhibited the growth of HepG2.2.15 cell in vitro.However,there was no concentration-depended effect.Loxoribine suppres...